Ganetespib
- Generic Name
- Ganetespib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20N4O3
- CAS Number
- 888216-25-9
- Unique Ingredient Identifier
- 2E8412Y946
- Background
Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 122
- Registration Number
- NCT03783949
- Locations
- 🇮🇹
Azienda Ospedaliero Bologna, Bologna, Italy
🇩🇪Universitätsklinikum Dresden, Dresden, Germany
🇦🇹Medical University of Innsbruck, Innsbruck, Austria
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT02637375
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
- Conditions
- Stage IIB Esophageal Cancer AJCC v7Stage IIIA Esophageal Cancer AJCC v7Malignant Neoplasm of the Cervical EsophagusMalignant Neoplasm of the Thoracic EsophagusStage IIA Esophageal Cancer AJCC v7Stage IIIC Esophageal Cancer AJCC v7Gastroesophageal Junction AdenocarcinomaStage IIIB Esophageal Cancer AJCC v7
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02389751
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ganetespib Window of Opportunity Study in Head and Neck Cancers
- Conditions
- Stage III Oropharyngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage II Hypopharyngeal Squamous Cell CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage I Laryngeal Squamous Cell CarcinomaStage II Laryngeal Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell CarcinomaStage III Laryngeal Squamous Cell CarcinomaStage IVA Hypopharyngeal Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT02334319
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 11
- Registration Number
- NCT02261805
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT02192541
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02060253
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 133
- Registration Number
- NCT02012192
- Locations
- 🇧🇪
Katholieke Universiteit Leuven, Dept. of Gynaecologic Oncology, Leuven, Belgium
🇩🇪Universitätsklinikum Hamburg-Eppendorf Dept. of Gynecology and Gynecologic Oncology, Hamburg, Germany
🇩🇪University Hospital Carl Gustav Carus Dresden, Department of Gynaecology and Obstetrics, Dresden, Germany
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-05-15
- Target Recruit Count
- 20
- Registration Number
- NCT02008877
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT01962948
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.